Skip to main content
Premium Trial:

Request an Annual Quote

Bernhard Kirschbaum and Oliver Schacht

Protagen has appointed Bernhard Kirschbaum as chairman of its supervisory board and Oliver Schacht as a new board member. Kirschbaum is a former Merck executive and has been a member of the Protagen board since 2015. He is taking over as the role of chairman from Axel Kleemann, who has served in the position for the past 15 years. Schacht successfully completed the IPO of Curetis last November, and has served in executive positions at Epigenomics in Seattle and in Berlin. He is currently a member of the executive board of BioDeutchland.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.